SCHEMBL6986797

SCHEMBL6986797

CCOc1c(Nc2cnccn2)c(=O)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
POLB P06746 2/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
KDM4E B2RXH2 4/20 0.43
RAB9A P51151 4/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 3/20 0.36
LYN P07948 1/20 0.36
SRC P12931 1/20 0.36
BTK Q06187 1/20 0.36
TP53 P04637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025790 0.79 GAA (0.57) TSHRPOLBGAAMAPTSMN1; SMN2
SCHEMBL4366566 0.78 GAA (0.49) POLBGAAMAPTSMN1; SMN2MAPKAPK2
SCHEMBL4023982 0.77 POLB (0.55) TSHRPOLBGAAMAPTSMN1; SMN2
SCHEMBL12784950 0.76 MAPKAPK2 (0.45) POLBMAPTSMN1; SMN2KDM4ERAB9A
SCHEMBL4023021 0.75 POLB (0.64) POLBGAAMAPTMAPKAPK2MAPK1
SCHEMBL7086793 0.72 MAPKAPK2 (0.40) TSHRMAPTSMN1; SMN2KDM4ERAB9A
SCHEMBL7347625 0.71 GAA (0.54) POLBGAAMAPTSMN1; SMN2KDM4E
SCHEMBL4370152 0.71 MAPT (0.45) POLBGAAMAPTKMT2AMEN1
SCHEMBL8995732 0.70 POLB (0.50) TSHRPOLBGAAMAPTSMN1; SMN2
SCHEMBL12092542 0.69 ALDH1A1 (0.52) POLBMAPTSMN1; SMN2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 TSHR 3942/4885POLB 2992/4885GAA 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.